Demographic and clinical characteristics of aGVHD response groups
| . | No aGVHD (n = 437) . | SS aGVHD (n = 99) . | SD aGVHD (n = 96) . | Steroid-refractory aGVHD (n = 152) . |
|---|---|---|---|---|
| Female sex, n (%) | 181 (41%) | 36 (36%) | 37 (39%) | 56 (37%) |
| Age at transplantation, y | ||||
| 0-17 | 113 (26%) | 15 (15%) | 4 (4%) | 15 (10%) |
| ≥18 | 324(74%) | 84 (85%) | 92 (96%) | 137 (90%) |
| Diagnosis category | ||||
| Acute leukemia | 312 (72%) | 75 (75%) | 63 (65%) | 99 (65%) |
| MDS | 52 (12%) | 9 (9%) | 10 (10%) | 22 (14%) |
| Multiple myeloma | 9 (2%) | 4 (4%) | 7 (7%) | 7 (5%) |
| Lymphoma | 58 (13%) | 10 (10%) | 14 (15%) | 14 (9%) |
| Myeloproliferative disorder/other | 6 (1%) | 1 (1%) | 2 (2%) | 10 (7%) |
| Donor | ||||
| Haploidentical | 35 (8%) | 1 (1%) | 3 (3%) | 4 (3%) |
| Matched sibling | 168 (38%) | 30 (30%) | 33 (34%) | 44 (29%) |
| UCB | 214 (49%) | 60 (61%) | 50 (52%) | 75 (49%) |
| URD | 20 (5%) | 8 (8%) | 10 (10%) | 29 (19%) |
| Conditioning intensity | ||||
| MAC | 194 (44%) | 45 (45%) | 44 (46%) | 61 (40%) |
| RIC | 243 (56%) | 54 (55%) | 52 (54%) | 91 (60%) |
| GVHD prophylaxis | ||||
| CsA/MTX | 77 (18%) | 20 (20%) | 12 (12%) | 19 (12%) |
| CsA/MMF | 246 (56%) | 66 (67%) | 78 (81%) | 105 (69%) |
| Sirolimus/MMF | 55 (13%) | 11 (11%) | 1 (1%) | 12 (8%) |
| Other | 59 (14%) | 2 (2%) | 5 (5%) | 16 (11%) |
| DRI | ||||
| Very high/high risk | 111 (25%) | 17 (17%) | 11 (11%) | 26 (17%) |
| Intermediate risk | 283 (65%) | 68 (69%) | 71 (74%) | 107 (70%) |
| Low risk | 43 (10%) | 14 (14%) | 14 (15%) | 19 (12%) |
| HCT comorbidity index | ||||
| 0 | 201 (46%) | 48 (48%) | 47 (49%) | 68 (45%) |
| 1-2 | 130 (30%) | 31 (31%) | 24 (25%) | 34 (22%) |
| 3+ | 106 (24%) | 20 (20%) | 25 (26%) | 50 (33%) |
| Karnofsky performance status | ||||
| <90 | 78 (18%) | 13 (13%) | 10 (10%) | 28 (18%) |
| ≥90 | 359 (82%) | 86 (87%) | 86 (90%) | 124 (82%) |
| MN GVHD risk | ||||
| High risk | 16 (16%) | 19 (20%) | 40 (26%) | |
| Standard risk | 83 (84%) | 77 (80%) | 112 (74%) |
| . | No aGVHD (n = 437) . | SS aGVHD (n = 99) . | SD aGVHD (n = 96) . | Steroid-refractory aGVHD (n = 152) . |
|---|---|---|---|---|
| Female sex, n (%) | 181 (41%) | 36 (36%) | 37 (39%) | 56 (37%) |
| Age at transplantation, y | ||||
| 0-17 | 113 (26%) | 15 (15%) | 4 (4%) | 15 (10%) |
| ≥18 | 324(74%) | 84 (85%) | 92 (96%) | 137 (90%) |
| Diagnosis category | ||||
| Acute leukemia | 312 (72%) | 75 (75%) | 63 (65%) | 99 (65%) |
| MDS | 52 (12%) | 9 (9%) | 10 (10%) | 22 (14%) |
| Multiple myeloma | 9 (2%) | 4 (4%) | 7 (7%) | 7 (5%) |
| Lymphoma | 58 (13%) | 10 (10%) | 14 (15%) | 14 (9%) |
| Myeloproliferative disorder/other | 6 (1%) | 1 (1%) | 2 (2%) | 10 (7%) |
| Donor | ||||
| Haploidentical | 35 (8%) | 1 (1%) | 3 (3%) | 4 (3%) |
| Matched sibling | 168 (38%) | 30 (30%) | 33 (34%) | 44 (29%) |
| UCB | 214 (49%) | 60 (61%) | 50 (52%) | 75 (49%) |
| URD | 20 (5%) | 8 (8%) | 10 (10%) | 29 (19%) |
| Conditioning intensity | ||||
| MAC | 194 (44%) | 45 (45%) | 44 (46%) | 61 (40%) |
| RIC | 243 (56%) | 54 (55%) | 52 (54%) | 91 (60%) |
| GVHD prophylaxis | ||||
| CsA/MTX | 77 (18%) | 20 (20%) | 12 (12%) | 19 (12%) |
| CsA/MMF | 246 (56%) | 66 (67%) | 78 (81%) | 105 (69%) |
| Sirolimus/MMF | 55 (13%) | 11 (11%) | 1 (1%) | 12 (8%) |
| Other | 59 (14%) | 2 (2%) | 5 (5%) | 16 (11%) |
| DRI | ||||
| Very high/high risk | 111 (25%) | 17 (17%) | 11 (11%) | 26 (17%) |
| Intermediate risk | 283 (65%) | 68 (69%) | 71 (74%) | 107 (70%) |
| Low risk | 43 (10%) | 14 (14%) | 14 (15%) | 19 (12%) |
| HCT comorbidity index | ||||
| 0 | 201 (46%) | 48 (48%) | 47 (49%) | 68 (45%) |
| 1-2 | 130 (30%) | 31 (31%) | 24 (25%) | 34 (22%) |
| 3+ | 106 (24%) | 20 (20%) | 25 (26%) | 50 (33%) |
| Karnofsky performance status | ||||
| <90 | 78 (18%) | 13 (13%) | 10 (10%) | 28 (18%) |
| ≥90 | 359 (82%) | 86 (87%) | 86 (90%) | 124 (82%) |
| MN GVHD risk | ||||
| High risk | 16 (16%) | 19 (20%) | 40 (26%) | |
| Standard risk | 83 (84%) | 77 (80%) | 112 (74%) |
MDS, myelodysplastic syndrome; MN, Minnesota; MTX, methotrexate.